Data Insights

Danvilostomig by Systimmune for Nasopharyngeal Cancer: Likelihood of Approval

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Nasopharyngeal Cancer

Data Insights

Danvilostomig by Systimmune for Gastrointestinal Tumor: Likelihood of Approval

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Gastrointestinal Tumor. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Gastrointestinal Tumor

Data Insights

Danvilostomig by Systimmune for Metastatic Colorectal Cancer: Likelihood of Approval

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Metastatic Colorectal Cancer

Data Insights

Danvilostomig by Systimmune for Esophageal Cancer: Likelihood of Approval

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Esophageal Cancer

Data Insights

Danvilostomig by Systimmune for Gastric Cancer: Likelihood of Approval

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Gastric Cancer

Data Insights

Danvilostomig by Systimmune for Gastric Cancer: Likelihood of Approval

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...